Simcha Therapeutics
New Haven
About Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer. The company uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simcha’s lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020. It was founded in 2018 and is headquartered in New Haven, Connecticut, USA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $65.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2022)
- Website: simchatx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/simcha-therapeutics-49345 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.